Citations

Mayo Clinic

Showing 10 of 108585 citations.

Care utilization and satisfaction among patients with cancer with neutropenic fever managed by a remote patient monitoring (RPM) program.
Haemmerle, Robert , Khera, Nandita , Leuenberger, Angela , Phillips, Sarah A. , Pahl, Dominick F. , Sangaralingham, Lindsey R. , Ryu, Alexander J. , Phelan, David, Gangat, Naseema , Molina, Julian R. , Tilburt, Jon C. , Haddad, Tufia C. , Pritchett, Joshua C. , Paludo, Jonas , Shi, Qian , Yetmar, Zachary A. , Wilson, John , McCoy, Rozalina G. , Kloft‐Nelson, Sara M. , Ryu, Alexander J. , Borah, Bijan J.

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 572-572

10.1200/op.2023.19.11_suppl.572 Get It

572 Background: The DEFeNDR (Decreasing the burden of Febrile Neutropenia through Dynamic RPM) program leverages in-home technology and centralized nurse monitoring to facilitate ambulatory management as an alternative to hospital-based care for cancer patients with neutropenic fever (NF). The objective of this study is to assess 30-day care utilization outcomes and patient satisfaction at 12 months after program implementation. Methods: Adult cancer patients hospitalized with NF were assessed daily for DEFeNDR program eligibility including MASCC score ≥21 (per ASCO guidelines) and no cellular therapy (CAR-T, BMT) in the prior 100 days. Patients agreeing to participate in the 30-day program received a cellular-enabled tablet with pre-connected devices for twice-daily vital signs and symptom assessments. Patient generated data were EHR-integrated in real-time. Embedded decision trees facilitated alerts for adverse trends. Virtual RPM nurses responded to alerts and utilized predefined care pathways. The primary endpoint was the mean proportion of evaluable days spent inpatient (mPEDI) within 30 days of eligibility comparing those who participated in the program (RPM) with those who declined (no RPM). Results: Of 85 eligible patients, 62 were offered DEFeNDR participation. Of those, 34 (54.8%) participated and 28 (45.2%) declined. Baseline characteristics and care utilization outcomes are summarized in Table 1. RPM patients experienced significantly lower mPEDI compared with unmonitored patients [5.1% (Standard Error [SE], 1.9%) vs 12.4% (SE, 2.1%); Wilcoxon Rank Sums p-value, 0.032]. RPM patients also experienced a trend toward fewer total hospital days and lower 30-day readmission rate, as well as shorter mean length of stay and lower rate of ICU utilization when readmitted. Non-visit care activities (EHR clinical communications, documentation, and patient messaging) were decreased from pre-hospital baseline for 58.8% of RPM patients versus 46.6% of those unmonitored. All RPM patients completing a patient satisfaction survey (n=9) indicated that they would recommend the program to patients with a similar condition. Conclusions: Cancer patients with NF participating in the DEFeNDR program experienced a significant reduction in mPEDI and care utilization compared with those who declined. Further studies are warranted to assess comparative effectiveness of this model vs usual care.[Table: see text]
Utilization of the medical oncology pager and call center: Characterizing forgotten pillars of telemedicine in the digital era.
Bentz, Caleb C., Godby, Richard , Hwang, Steven R. , Paludo, Jonas , Go, Ronald S.

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 518-518

10.1200/op.2023.19.11_suppl.518 Get It

518 Background: Oncology has entered the digital era, accompanied by changes in patient interactions and expectations involving telemedicine. While much emphasis is appropriately placed on digital interactions with patients, little is known about modern non-digital interactions with patients in oncology practices. Methods: We analyzed Medical Oncology Pager (MOP) data from 7/1/18 – 4/14/23, during which patients had access to the electronic health record and messaging capabilities. The MOP for Mayo Clinic (Rochester) is covered by the medical oncology fellows, including after hours (6PM – 7AM). It covers consults and direct patient calls after hours and during weekends, in addition to critical results back up and inpatient oncology matters at all times. We also analyzed Medical Oncology Call Center (MOCC) data since 6/1/22, which takes inbound patient calls during working hours (7AM – 6PM) and is staffed by appointment office employees. Results: The MOP received a total of 17,679 pages during the analyzed period for a mean of 10.1 pages per day. Of these, 6,319 pages occurred after hours. The most after-hours pages were received on Fridays (n=1,091) and the least on Sundays (n=701); of those years with fully available data, 2022 had the highest volume (n=1,405) (Table 1). When comparing the MOP activity pre-pandemic (7/1/18 – 3/10/20) and intra-pandemic (3/11/20 – 4/14/23), the mean number of after-hours pages per day was relatively stable with 3.47 pre-pandemic and 3.69 intra-pandemic. Since 6/1/22, the MOCC has averaged 6,464 inbound calls per month during working hours, each of which had an average talk time of approximately five minutes. The majority of inbound calls occur on Monday mornings between 9 – 11AM, with over 6,500 recorded throughout the previous year. Conclusions: Telemedicine is multi-faceted, comprised of both digital and non-digital patient interactions. We show that many oncology patients utilize telephone communication with the healthcare system despite increased availability of digital capabilities. These data have implications for addressing the digital divide for those with limited digital access, serving older patient populations unfamiliar with digital technologies, healthcare navigation, trainee responsibilities, and resource allocation. Further work and standardization in non-digital telemedicine is necessary as it remains a pillar of modern healthcare delivery and oncology practices.[Table: see text]
Quality improvement project to improve smoking cessation among an oncology cohort at a large US multistate cancer center.
Ohde, Joshua W. , Jose, Thulasee , Warner, David O.

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 435-435

10.1200/op.2023.19.11_suppl.435 Get It

435 Background: Assessing tobacco use and providing cessation support is recommended by the American Society for Clinical Oncology (ASCO). As part of the National Cancer Institute Cancer Center Cessation Initiative, we established an electronic health record based "opt-out" approach to refer patients to tobacco treatment specialists. However, the role of oncologists in contributing to the “opt-out” approach to patients has not been explored. We tested the hypothesis that a multi-component educational program for oncologists would increase the proportion of patients who completed tobacco treatment appointments. Methods: As a quality improvement initiative, oncology providers at the Rochester Mayo Clinic Cancer Center were educated using a multimodal academic detailing approach with group and individual educational sessions. Its effectiveness was tested using a modified step-wedge implementation design. The primary outcomes were patient behaviors that could plausibly be changed by conversations with their provider: the rate at which cancer patients identified as current tobacco users scheduled an appointment in the Nicotine Dependence Center, and the rate at which patients scheduled for a NDC appointment completed their appointment. Comparisons were made before, during, and after the education period (from July through Dec 2019) and with a separate group of providers who did not complete education (results examined over a similar time period). Results: Education intervention did not improve outcomes among providers who received education; indeed, the rate of appointment scheduling decreased, although this may reflect other concurrent changes in the tobacco treatment referral process (Table 1). Outcomes were similar between oncology providers who did and did not receive multicomponent education intervention. Conclusions: Smoking cessation efforts can be successfully integrated into routine cancer care. The implementation of the “opt-out” referral system resulted in approximately 1 in 5 patients being seen for tobacco use, but a multicomponent education intervention designed to equip oncologists to encourage patients to complete appointments was not effective. Novel approaches are needed to increase the uptake of tobacco treatment among patients.[Table: see text]
Geriatric pre-surgical optimization in the NCORP (Alliance).
Finlayson, Emily , Gunn, Heather, Barber, Anne, Lowenstein, Lisa M. , Dohan, Daniel , Dockter, Travis , Tan, Angelina D., Bailey, Lisa, Chow, Selina , Wills, Rachel, Jatoi, Aminah , Lee, Eugene K. , Gills, Jessie, Mulligan, Charles R., Hayseen, Therese, Chang, George J. , Broering, Jeanette M. , Dueck, Amylou C. , Delacroix, Scott Edward

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 370-370

10.1200/op.2023.19.11_suppl.370 Get It

370 Background: Mounting evidence suggests tailored preparation targeting geriatric vulnerabilities can improve functional outcomes after major surgery in older adults. Although many surgeons express interest in surgical optimization of older patients, few practices have the time or expertise to deliver geriatric prehabilitation before surgery. This study investigated the effectiveness of OPTI-Surg, a frailty prehabilitation toolkit, for improving surgical outcomes. In this abstract, we report adherence to the OPTI-Surg toolkit in the intervention arm. Methods: Thoracic (T), gastrointestinal (GI), and urologic (GU) oncological surgery practices affiliated with NCI’s Community Oncology Research Program (NCORP) were randomized 1:1:1, stratified by practice type, to usual care (control), OPTI-Surg toolkit, or OPTI-Surg with an implementation coach. The toolkit was implemented at the practice level and consisted of the 12-item Edmonton Frail Scale (EFS) and guided recommendations for interventions including referrals directed at identified vulnerabilities. Eligible patients were ≥70 years old and undergoing curative intent surgery for T, Gl, or GU cancers. Results: From July 2019 to October 2021, 155 patients were enrolled in the OPTI-Surg intervention arm. The EFS was administered to 153 (98.7%) of the enrolled patients, 143 of whom went on to have surgery. Overall, 134 (93.7%) surgical patients had at least one deficit identified on the EFS assessment and 55 (41.0%) of these patients received a recommended referral intended to optimize surgical outcomes. Among the 55 patients who received referrals, 44 (80.0%) followed through on the referral. Individual deficit rates were highest for medication use, general health status, and functional performance, and referrals were most frequently made for deficits in continence and functional independence (Table). Conclusions: In the OPTI-Surg geriatric surgical optimization trial, implementation of the frailty screening with the EFS assessment was successful. Rates of recommended referrals for patients with identified deficits, however, were low. When referred, most patients followed through for targeted prehabilitation. Clinical trial information: NCT03857620 .[Table: see text]
Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial.
Umashankar, Saumya , Musthafa, Mina, Jones, Tamia, Blevins, Kaylee, Brown, Thelma, Heditsian, Diane , Parker, Beverly, Brain, Susie, Simmons, Carol A., Ruddy, Kathryn J. , Mainor, Candace , Tevis, Sarah , Dunn, Imogene, Melisko, Michelle , Basu, Amrita B , Simmons, Carol, Hieken, Tina J. , Blaes, Anne , Rugo, Hope S. , Esserman, Laura J. , Hershman, Dawn L.

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 369-369

10.1200/op.2023.19.11_suppl.369 Get It

369 Background: Patient-reported outcomes (PROs) are a valuable component to understand treatment tolerability and toxicity. We have implemented an electronic system for monitoring PROs and quality of life (QOL) for patients enrolled in the I-SPY2 trial, a phase II trial evaluating the effect of novel neoadjuvant therapies for breast cancer. We associated patient demographic factors with symptoms, decline in physical function (PF), and tolerability to treatment. Methods: Study population for this analysis includes 259 enrolled patients receiving combinations of experimental immunotherapy and chemotherapy. Patients completed PRO-CTCAE/PROMIS/FACT surveys reflecting symptom severity, symptom frequency, tolerability of drug, and physical function at baseline through follow up (12 months). CTCAE 5.0 was collected weekly at these timepoints to assess adverse events (AE). Odds ratio and regularized multi-variate regression was used to evaluate early symptoms predictive of a clinically significant decline in PF from baseline to post-treatment follow-up. Results: Of 259 patients, 160 (58%) were White, 13 (5%) were Asian, 26 (10%) were African American (AA), and 25 (9.3%) were Hispanic. 25% of all patients had a clinically significant decline in PF between baseline and pre-surgery/follow-up. Symptom predictors of decline included high frequency of diarrhea and severity of joint pain. African American (AA) patients had higher severity of joint pain than White patients (OR = 14.9, P < 0.05). Within the first 12 weeks of treatment, AA patients and non-white (NW) patients were more likely to report severe vomiting than White patients (OR =13.22 and 12.72, P< 0.05 and P< 0.03 respectively). Overall, patients that reported lower tolerance to therapy had higher grade of AE. While patients with low-grade adverse events were less bothered by their side effects at follow-up, higher grade adverse events such as hypothyroidism impacted distress levels by more than double. Conclusions: Among I-SPY2 participants, when higher grade of symptoms is persistent through follow up, it impacts physical function and tolerability even after end of therapy. Our study can allow physicians to be more diligent in active and post treatment monitoring. Clinical trial information: NCT01042379 .
Patient and nursing staff perspectives on automated scalp cooling (ASC) for chemotherapy-induced alopecia in breast cancer.
Ueberroth, Benjamin E. , Nafissi, Nellie , Ertz-Archambault, Natalie , Haddad, Tufia C. , Northfelt, Donald W. , Kosiorek, Heidi

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 365-365

10.1200/op.2023.19.11_suppl.365 Get It

365 Background: Automated scalp cooling (ASC) is utilized in breast cancer patients to reduce chemotherapy-induced alopecia. Nursing staff and patient perspectives on ASC are limited regarding impact on care delivery and outcomes. Methods: A survey-based study of patient and chemotherapy nurse perspectives of ASC was conducted at three multi-regional Mayo Clinic sites. One-time surveys were sent to breast cancer patients and nurses for self-reporting of the ASC experience. Patients were identified via ICD-10 codes for breast cancer with subsequent chart review to confirm relevant chemotherapy regimen and ASC use. Chemotherapy nurses were identified by their respective chemotherapy unit nurse managers. Patient survey responses were compared between groups that did or did not use ASC by use of Pearson chi-square test for frequency data and the Kruskal-Wallis rank sum test for continuous measures. P values <0.05 were considered statistically significant. Results: Surveys were sent to 181 nurses with 61 (33.7%) completing them. Nurses reported ASC administration to 10-50 patients (n=43, 63.9%) or ≥50 patients (n=18, 29.5%). Most felt they had little or no technical support available (67.2%), witnessed scheduling difficulties (52.5%), were distressed by workload intensity (52.5%), and did not receive adequate training (67.2%). Most felt that ASC demanded greater nursing time compared to other duties (57.4%). Most would not recommend ASC to a friend or family member (88.6%). Surveys were sent to chemotherapy patients with 93 of 465 (20.0%) ASC patients and 56 of 341 (16.4%) without ASC (control) completing them. Controls were significantly more likely to experience hair loss, shave their head, and wear a wig (all p<0.001). There was no significant difference between groups for the EORTC QLQC30, EORTC BR23, and Body Image Scale results or frequency of headaches. Patients who used ASC for less than half of their chemotherapy sessions reported significantly more cold discomfort ( p=0.040) and dizziness ( p=0.003). Time investment (33.3%) and side effects (31.2%) were the most frequent burdens cited. Conclusions: Most nurses indicated that ASC increased nursing workload compared with other duties, and they lacked adequate training and technical support. Increasing formal nurse education and access to technical support documents and live technical support may be options for improving nursing satisfaction with ASC. Patient responses suggest qualitative effectiveness of ASC in reducing hair loss. While those with ASC were less likely to shave or use a wig, this did not translate to significant differences in quality of life or psychosocial body image compared to controls. Cold discomfort and dizziness were the most frequent side effects among those with lower utilization of ASC.
Health insurance literacy among patients receiving outpatient cancer treatment.
Zhang, Nan , Khera, Nandita , Zhao, Jingxuan , Hilal, Talal , Griffin, Joan M. , Yabroff, K. Robin

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 339-339

10.1200/op.2023.19.11_suppl.339 Get It

339 Background: Limited health insurance literacy (HIL) has been linked to problems paying medical bills or delaying care among patients with cancer. In this study, we describe the prevalence and correlates of HIL in a cohort of cancer patients measured using a ten-question HIL quiz developed by the Kaiser Family Foundation. Methods: We examined HIL in 393 adult patients (aged >18 years) receiving cancer treatment in two ambulatory infusion centers, Mayo Clinic in Phoenix, Arizona (12/2019 to 2/2020 and 8/2020 to 10/2020) and University of Mississippi Medical Center in Jackson, Mississippi (9/2020 to 1/2021). HIL was categorized as low, moderate, or high based on the total number of correct answers: 0-4 (low), 5-6 (moderate), and 7-10 (high). Descriptive statistics characterized the sample and chi-square statistics compared HIL by sociodemographic factors. Results: Most patients understood basic insurance terms, such as premiums and deductibles (Table). However, fewer patients answered questions correctly about provider networks (46.1%), formularies (48.6%), and calculating out-of-pocket (OOP) spending (16.8%). 53 (13.5%), 69 (17.6%), and 271 (69.0%) patients had low, moderate, and high HIL scores, respectively. Lower HIL was more common among patients of younger age (<65 years: 17.8%, 65+ years: 8.7%), lower educational attainment (less than college: 23.2%; college or higher: 4.4%), and lower household income (<$4999: 21.1%, $5000+: 6.1%) (all p-values<0.05). Conclusions: Although HIL in our cohort of cancer patients was relatively high - 69% answered at least 7 questions correctly - there were gaps in understanding of provider networks, formularies, and calculation of OOP spending. Efforts to improve HIL and help with navigation of health insurance plans may be required, especially for socioeconomically vulnerable patients.[Table: see text]
Decision aid and patient engagement in breast surgical consults: A treatment-compliant analysis of Alliance A231701CD.
Zahrieh, David M. , Tucholka, Jennifer L. , Tan, Angelina D., Breuer, Catherine R. , Bailey, Lisa, Higham, Anna M. , Wecsler, Julie S. , Arnold, Alicia H, Froix, Anthony J. , Dull, Scott, Abbott, Andrea M. , Fine, Stephanie , McGuire, Kandace P. , Seydel, Anna S. , Chow, Selina , Neuman, Heather B. , Schumacher, Jessica R. , Hanlon, Bret M. , Rathouz, Paul J. , Arnold, Alicia , McNamara, Patricia

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 314-314

10.1200/op.2023.19.11_suppl.314 Get It

314 Background: In a recent trial, we observed no statistically significant increase in engagement after a web-based decision aid (DA) was delivered to breast cancer patients prior to a surgical consult. However, a minority of the intervention group (44%) reviewed the DA. The objective is to assess the effect of the DA on engagement for the cohort of patients who reviewed it. Methods: A stepped wedge trial was conducted with 10 NCI Community Oncology Research Program clinics that care for a high proportion of socioeconomically disadvantaged patients (6/2019-12/2021). Clinics were randomized to time of transition from usual care (UC) to delivery of a DA. Patients with stage 0-3 breast cancer eligible for surgery provided consent prior to a surgical consult. Engagement was measured from audio-recorded surgical consults (Active Patient Behaviors, Street protocol). For this analysis, we identified a cohort of treatment compliant (TC) patients who reviewed the DA. Intervention effects comparing TC and UC groups were tested with linear mixed-effects models, accounting for time, enrollment post-COVID, and patient age, race, education, and socioeconomic disadvantage (assessed with Area Deprivation Index and dichotomized). Exploratory models were generated using Active Patient Behavior subcomponents (asking questions, assertive responses, expressions of concern) as the outcome. Results: The cohort includes 407 patients (UC 264; TC 143). TC patients were more likely to be white (TC 73%, UC 64%, p=0.03), have a college degree (TC 65%, UC 55%, p=0.05), and not be disadvantaged (TC 89%, UC 72%, p=0.001). TC was associated with increased engagement (8.2 [0.08, 16.2], p=0.048, Table). A college degree was associated with higher, while black race and socioeconomic disadvantage lower, engagement. On exploratory analyses, TC had a stronger association with higher levels of assertive responses (2.9 [-0.3, 6.1], p=0.07) compared with asking questions (5.2 [-1.4, 11.9], p=0.12) or expressions of concern (0.08 [-0.60, 0.76], p=0.82). Conclusions: We observed increased engagement in breast cancer patients who reviewed a DA prior to a surgical consult. However, we also observed differences based on race, education, and socioeconomic disadvantage. Further research will identify adjunct interventions to combine with the DA to improve cancer care delivery for diverse populations. Support: UG1 CA189823; AHRQ R01HS025194; https://acknowledgments.alliancefound.org. Clinical trial information: NCT03766009 .[Table: see text]
Uptake of palliative care services in patients with non-small cell lung cancer receiving immune checkpoint inhibitor therapy: The Mayo Clinic Florida experience.
Pai, Tanmayi , Li, Shenduo , Correia, Guilherme Sacchi de Camargo, Butts, Emily, Taylor, Richard C., Zhao, Yujie , Lou, Yanyan , Mosalem, Osama , Wiest, Nathaniel E. , Taylor, Richard C, Manochakian, Rami

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 269-269

10.1200/op.2023.19.11_suppl.269 Get It

269 Background: There are strong data showing that patients (pts) with metastatic non-small cell lung cancer (NSCLC) receiving chemotherapy experience better quality of life (QOL) and longer overall survival (OS) when palliative care (PC) services are integrated early in their treatment course. Therefore, at our cancer center, pts with stage IV NSCLC have been referred to PC by oncology providers. In this study, we evaluated the uptake of PC services, specifically in pts with NSCLC who received immune checkpoint inhibitors (ICIs). ICIs have been considered to have less severe or less frequent adverse effects as compared to chemotherapy, possibly leading to fewer referrals to PC. Methods: We conducted a retrospective review of all pts at the Mayo Clinic Cancer Center in Florida who received single-agent ICI therapy for the treatment of stage IV NSCLC at any point between July 1, 2015, and July 1, 2022. The primary aim was to evaluate the uptake of PC services before or during treatment with ICIs. Descriptive statistics were used to characterize pt demographics and outcomes. Results: 129 pts were identified. 53.4% were male, and 46.6% were female. The majority of pts (84.4%) were white. 62 pts (48.0%) were seen by a PC provider before or during ICI treatment; 41 of these (31.7%) were seen by PC after starting ICI therapy. When grouped by year of ICI initiation, 30/73 pts (41.0%) treated between 2015 and June 2018 were seen by a PC provider, as compared to 15/31 pts (48.3%) treated between July 2018 and June 2020 and 17/25 pts (68.0%) treated between July 2020 and July 2022. Interestingly, the majority of pts who received PC services in the 2020-2022 group (12/17, or 70.5%) were seen by a PC provider for the first time prior to ICI initiation, whereas the majority of pts who received PC services prior to July 2020 (37/45, or 82.2%) were seen by a PC provider for the first time after ICI initiation. The mean number of PC visits increased from 1.59 in the 2015-2018 group to 1.84 in the 2018-2020 group and 4.96 in the 2020-2022 group. Conclusions: Uptake of PC services in pts with stage IV NSCLC receiving single-agent ICIs at our cancer center has increased over time, which is encouraging. Nevertheless, the numbers remain suboptimal, with less than 70% of pts receiving PC services. We plan to develop a multidisciplinary quality improvement project involving implementation of a mechanism to ensure that most patients with stage IV NSCLC, regardless of the type of systemic treatment they receive, are receiving PC services.
Breaking barriers: Effective interventions amplifying minority participation in cancer clinical trials.
Pottinger, David Lewis , Gaskin, Regan, Mehta, Amitkumar , Fouad, Mona N. , Niranjan, Soumya J , Desai, Aakash

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 201-201

10.1200/op.2023.19.11_suppl.201 Get It

201 Background: Cancer-related mortality is disproportionately higher in marginalized populations, necessitating adequate representation in cancer clinical trials. Historically, this goal has been challenging, despite recognition of the importance for clinical practice. Moreover, minority recruitment has decreased in oncology clinical trials published from 2003-2016, indicating an urgent need for effective interventions for this issue. Methods: We conducted a systematic review of interventions focused on increasing minority recruitment/retention in cancer clinical trials between 2012-2023, or on improving attitudes of minority groups towards enrollment. We queried Embase and Scopus databases for articles/abstracts that focused on underrepresented ethnic minority enrollment in cancer clinical trials, in English language, were conducted in the US, Canada, Australia, New Zealand, or Western Europe, and were investigating effectiveness of interventions to improve minority enrollment in adult populations. Results: 261 unique articles/abstracts met our search criteria, with an additional 55 duplicates. 117 were removed for being irrelevant or too old, 31 for being reviews, 85 due to not containing an intervention, 5 for not reporting minority data, and 6 for not adequately comparing the strength of interventions. 17 met all inclusion criteria. Several interventions were identified, including targeted patient education (n=7), assigning patient navigators (n=6), community organization engagement (n=3), nested family/community approaches (n=2), and financial assistance (n=1). Targeted education involved video, audio, or interactive mediums. Most studies involved Black (n=12) and Hispanic (n=5) populations, with a smaller number focusing on Asian/Asian Pacific Islanders (n=2), Arabs (n=1), and Indian/South Asians (n=1). Geographically, these studies were notably concentrated in the American South (n=7). The Midwest and Mid-Atlantic regions contributed equally (n=3 each), and fewer studies were from the Northeast and West (n=2 each). Conclusions: Racial minorities continue to be underrepresented in cancer clinical trials, underscoring the need for concerted efforts to promote healthcare equity and enhance these trials’ generalizability. In our systematic review, targeted education, patient navigators, and active community engagement emerged as efficacious strategies, and were the most frequently utilized to bolster minority enrollment. Future studies should prioritize investigating and implementing these interventions, to ensure diverse, representative, and applicable clinical trial participation.